2023-02-15

Camurus' Full Year Report 2022

Fluidcrystal Injection Depot 1

Camurus' Full Year Report for 2022 was published on February 14. 2022 was the first profitable year for Camurus, driven by strong sales growth.

"We ended the year with a fourth quarter with excellent performance across the organization, strong sales momentum, positive operating results, and continued pipeline progress. Camurus reported full year profitability for the first time while also investing half a billion SEK in our R&D pipeline", says Fredrik Tiberg, President & CEO.

Read the full report on Camurus' website: 

Camurus’ Full Year Report 2022 - Camurus

Latest news

2019-08-26

Camurus’ treatment Buvidal® subsidised in Australia

Australia has announced that Camurus’ treatment Buvidal® (buprenorphine) will be listed through the Pharmaceutical B…

Read more

2019-08-07

Three new products from ISEC

ISEC has launched three new products for better and safer surveillance of radioactive environments.

Read more

2019-07-23

Positive outcome for Camurus in court proceedings regarding final approval of Brixadi™ in the US

Camurus’ partner Braeburn have received a positive outcome in the US court proceedings which were initiated in April…

Read more

2019-06-20

FDA grants Camurus IND application to enter Phase 3 study with CAM2029 for treatment of acromegaly

The FDA has approved Camurus’ Investigational New Drug application to initiate a Phase 3 study with CAM2029 once-mon…

Read more

2019-06-17

Introducing the chemical-free office

Starting June 2019, all Sandberg Development's office and production facilities will be cleaned and washed with DIRO…

Read more